Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma.

Schoenfeld JD, Gjini E, Rodig SJ, Tishler RB, Rawal B, Catalano PJ, Uppaluri R, Haddad RI, Hanna GJ, Chau NG, Rabinowits G, Lorch J, Jo VY, Krane JF, Goguen LA, Annino DJ, Abdelrahman S, Lipschitz M, Margalit DN.

Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):137-145. doi: 10.1016/j.ijrobp.2018.05.002. Epub 2018 Jun 29.

PMID:
29960819
2.

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.

Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG.

N Engl J Med. 2018 Jul 26;379(4):341-351. doi: 10.1056/NEJMoa1805131. Epub 2018 Jun 4.

PMID:
29863979
3.

A case of Graves' ophthalmopathy associated with pembrolizumab (Keytruda) therapy.

Park ESY, Rabinowits G, Hamnvik OR, Dagi LR.

J AAPOS. 2018 Aug;22(4):310-312. doi: 10.1016/j.jaapos.2018.01.006. Epub 2018 Apr 4.

PMID:
29626663
4.

Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial.

D'Angelo SP, Russell J, Lebbé C, Chmielowski B, Gambichler T, Grob JJ, Kiecker F, Rabinowits G, Terheyden P, Zwiener I, Bajars M, Hennessy M, Kaufman HL.

JAMA Oncol. 2018 Sep 1;4(9):e180077. doi: 10.1001/jamaoncol.2018.0077. Epub 2018 Sep 13.

5.

Cabozantinib in Patients with Advanced Merkel Cell Carcinoma.

Rabinowits G, Lezcano C, Catalano PJ, McHugh P, Becker H, Reilly MM, Huang J, Tyagi A, Thakuria M, Bresler SC, Sholl LM, Shapiro GI, Haddad R, DeCaprio JA.

Oncologist. 2018 Jul;23(7):814-821. doi: 10.1634/theoncologist.2017-0552. Epub 2018 Feb 14.

PMID:
29445030
6.

Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study.

Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD Jr, Misiwkeiwicz K, Thomas T, Nehs M, Marqusee E, Lee SL, Jänne PA, Lorch JH.

Clin Cancer Res. 2018 Apr 1;24(7):1546-1553. doi: 10.1158/1078-0432.CCR-17-2297. Epub 2018 Jan 4.

PMID:
29301825
7.

Consider Surgery, but Not in This Case.

Rabinowits G, Yoon C, Thakuria M.

Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):16. doi: 10.1016/j.ijrobp.2017.08.032. No abstract available.

PMID:
29254771
8.

The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline.

Sultan A, Hanna GJ, Margalit DN, Chau N, Goguen LA, Marty FM, Rabinowits G, Schoenfeld JD, Sonis ST, Thomas T, Tishler RB, Treister NS, Villa A, Woo SB, Haddad R, Mawardi H.

Oncologist. 2017 Nov;22(11):1413. doi: 10.1634/theoncologist.2016-0298erratum. No abstract available.

9.

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, Wei Z, Palakurthi S, Bittinger M, Vitzthum H, Kim JW, Merlino A, Quinn M, Venkataramani C, Kaplan JA, Portell A, Gokhale PC, Phillips B, Smart A, Rotem A, Jones RE, Keogh L, Anguiano M, Stapleton L, Jia Z, Barzily-Rokni M, Cañadas I, Thai TC, Hammond MR, Vlahos R, Wang ES, Zhang H, Li S, Hanna GJ, Huang W, Hoang MP, Piris A, Eliane JP, Stemmer-Rachamimov AO, Cameron L, Su MJ, Shah P, Izar B, Thakuria M, LeBoeuf NR, Rabinowits G, Gunda V, Parangi S, Cleary JM, Miller BC, Kitajima S, Thummalapalli R, Miao B, Barbie TU, Sivathanu V, Wong J, Richards WG, Bueno R, Yoon CH, Miret J, Herlyn M, Garraway LA, Van Allen EM, Freeman GJ, Kirschmeier PT, Lorch JH, Ott PA, Hodi FS, Flaherty KT, Kamm RD, Boland GM, Wong KK, Dornan D, Paweletz CP, Barbie DA.

Cancer Discov. 2018 Feb;8(2):196-215. doi: 10.1158/2159-8290.CD-17-0833. Epub 2017 Nov 3.

PMID:
29101162
10.

Is this the end of cytotoxic chemotherapy in Merkel cell carcinoma?

Rabinowits G.

Onco Targets Ther. 2017 Sep 28;10:4803-4807. doi: 10.2147/OTT.S126640. eCollection 2017. Review.

11.

Patient-oriented toxicity endpoints after head and neck reirradiation with intensity modulated radiation therapy.

Margalit DN, Schoenfeld JD, Rawal B, Haddad RI, Catalano PJ, Goguen LA, Chau NG, Rabinowits G, Lorch JH, Annino DJ, Tishler RB.

Oral Oncol. 2017 Oct;73:160-165. doi: 10.1016/j.oraloncology.2017.08.012. Epub 2017 Sep 8.

PMID:
28939070
12.

Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer.

Rabinowits G, Bowden M, Flores LM, Verselis S, Vergara V, Jo VY, Chau N, Lorch J, Hammerman PS, Thomas T, Goguen LA, Annino D, Schoenfeld JD, Margalit DN, Tishler RB, Haddad RI.

Front Oncol. 2017 Aug 29;7:191. doi: 10.3389/fonc.2017.00191. eCollection 2017.

13.

Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma.

Hanna GJ, Sridharan V, Margalit DN, La Follette SK, Chau NG, Rabinowits G, Lorch JH, Haddad RI, Tishler RB, Anderson KS, Schoenfeld JD.

Cancer Biomark. 2017;19(2):129-136. doi: 10.3233/CBM-160071.

PMID:
28387659
14.

The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline.

Sultan A, Hanna GJ, Margalit DN, Chau N, Goguen LA, Marty FM, Rabinowits G, Schoenfeld JD, Sonis ST, Thomas T, Tishler RB, Treister NS, Villa A, Woo SB, Haddad R, Mawardi H.

Oncologist. 2017 Mar;22(3):343-350. doi: 10.1634/theoncologist.2016-0298. Epub 2017 Feb 16. Review. Erratum in: Oncologist. 2017 Nov;22(11):1413.

15.

Merkel Cell Polyomavirus Exhibits Dominant Control of the Tumor Genome and Transcriptome in Virus-Associated Merkel Cell Carcinoma.

Starrett GJ, Marcelus C, Cantalupo PG, Katz JP, Cheng J, Akagi K, Thakuria M, Rabinowits G, Wang LC, Symer DE, Pipas JM, Harris RS, DeCaprio JA.

MBio. 2017 Jan 3;8(1). pii: e02079-16. doi: 10.1128/mBio.02079-16.

16.

Successful Management of a Patient with Malignant Thyroid Teratoma.

Rabinowits G, Barletta J, Sholl LM, Reche E, Lorch J, Goguen L.

Thyroid. 2017 Jan;27(1):125-128. doi: 10.1089/thy.2016.0201. Epub 2016 Nov 28.

PMID:
27784193
17.

Merkel Cell Carcinoma: A Population Analysis on Survival.

Sridharan V, Muralidhar V, Margalit DN, Tishler RB, DeCaprio JA, Thakuria M, Rabinowits G, Schoenfeld JD.

J Natl Compr Canc Netw. 2016 Oct;14(10):1247-1257.

PMID:
27697979
18.

Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer.

Sridharan V, Margalit DN, Lynch SA, Severgnini M, Zhou J, Chau NG, Rabinowits G, Lorch JH, Hammerman PS, Hodi FS, Haddad RI, Tishler RB, Schoenfeld JD.

Br J Cancer. 2016 Jul 12;115(2):252-60. doi: 10.1038/bjc.2016.166. Epub 2016 Jul 5.

19.

Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.

Chau NG, Li YY, Jo VY, Rabinowits G, Lorch JH, Tishler RB, Margalit DN, Schoenfeld JD, Annino DJ, Goguen LA, Thomas T, Becker H, Haddad T, Krane JF, Lindeman NI, Shapiro GI, Haddad RI, Hammerman PS.

Clin Cancer Res. 2016 Jun 15;22(12):2939-49. doi: 10.1158/1078-0432.CCR-15-2314. Epub 2016 Jan 13.

20.

Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience.

Lorch JH, Hanna GJ, Posner MR, O'Neill A, Thotakura VL, Limaye SA, Rabinowits G, Sher DJ, Tishler RB, Haddad RI.

Head Neck. 2016 Apr;38 Suppl 1:E1618-24. doi: 10.1002/hed.24289. Epub 2015 Nov 28.

PMID:
26614576
21.

Merkel Cell Carcinoma Presenting as Subcutaneous Breast Masses: An Uncommon Presentation of a Rare Neuroendocrine Neoplasm.

Nambudiri VE, Vivero M, Watson AJ, Thakuria M, Ng A, Russell S, Rabinowits G, LeBoeuf NR.

Breast J. 2016 Jan-Feb;22(1):113-5. doi: 10.1111/tbj.12534. Epub 2015 Nov 25. No abstract available.

PMID:
26607182
22.

Optimizing Tobacco Cessation Resource Awareness Among Patients and Providers.

Ma L, Donohue C, DeNofrio T, Vitale Pedulla L, Haddad RI, Rabinowits G.

J Oncol Pract. 2016 Jan;12(1):e77-82. doi: 10.1200/JOP.2015.005124. Epub 2015 Sep 1.

PMID:
26330532
23.

Merkel cell carcinoma in a patient with GATA2 deficiency: a novel association with primary immunodeficiency.

Crall C, Morley KW, Rabinowits G, Schmidt B, Dioun Broyles A, Huang JT.

Br J Dermatol. 2016 Jan;174(1):169-71. doi: 10.1111/bjd.14062. Epub 2015 Nov 3.

PMID:
26252413
24.

Human papillomavirus-associated oropharynx cancer (HPV-OPC): treatment options.

Chau NG, Rabinowits G, Haddad RI.

Curr Treat Options Oncol. 2014 Dec;15(4):595-610. doi: 10.1007/s11864-014-0309-1. Review.

PMID:
25240410
25.

Update on the biology and clinical management of Merkel cell carcinoma.

Thakuria M, LeBoeuf NR, Rabinowits G.

Am Soc Clin Oncol Educ Book. 2014:e405-10. doi: 10.14694/EdBook_AM.2014.34.e405. Review.

26.

Systemic Therapy for Merkel Cell Carcinoma: What's on the Horizon?

Rabinowits G.

Cancers (Basel). 2014 May 16;6(2):1180-94. doi: 10.3390/cancers6021180.

27.

Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.

Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, Limaye S, Riley S, Posner M.

Lancet Oncol. 2013 Mar;14(3):257-64. doi: 10.1016/S1470-2045(13)70011-1. Epub 2013 Feb 13.

PMID:
23414589
28.

In-hospital and long-term outcomes after percutaneous endoscopic gastrostomy in patients with malignancy.

Keung EZ, Liu X, Nuzhad A, Rabinowits G, Patel V.

J Am Coll Surg. 2012 Dec;215(6):777-86. doi: 10.1016/j.jamcollsurg.2012.08.013. Epub 2012 Sep 19.

PMID:
22999329
29.

Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature.

Rabinowits G, Haddad RI.

Oral Oncol. 2012 Nov;48(11):1085-9. doi: 10.1016/j.oraloncology.2012.06.016. Epub 2012 Jul 25. Review.

PMID:
22840785
30.

Fixed-dose every-other-week capecitabine and oxaliplatin for refractory squamous cell carcinoma of the head and neck.

Rabinowits G, Bhupalam L, Miller DM, Kloecker GH, Laber DA.

Am J Med Sci. 2010 Feb;339(2):148-51. doi: 10.1097/MAJ.0b013e3181c4bd91.

PMID:
20087165
31.

Bladder cancer: clinical practice.

Rabinowits G, Laber DA.

J Ky Med Assoc. 2009 Apr;107(4):129-33. Review. No abstract available.

PMID:
19419018
32.

Exosomal microRNA: a diagnostic marker for lung cancer.

Rabinowits G, Gerçel-Taylor C, Day JM, Taylor DD, Kloecker GH.

Clin Lung Cancer. 2009 Jan;10(1):42-6. doi: 10.3816/CLC.2009.n.006.

PMID:
19289371
33.

Indolent course of thymic carcinoid.

Rabinowits G, Shuster TD, Pazianos AG, Laber DA.

J Clin Oncol. 2007 Mar 20;25(9):1138-9. No abstract available.

PMID:
17369578
34.

Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine.

Rabinowits G, Herchenhorn D, Rabinowits M, Weatge D, Torres W.

Anticancer Drugs. 2003 Sep;14(8):665-8.

PMID:
14501391

Supplemental Content

Loading ...
Support Center